Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Successful implementation of an automated electronic support system for patient safety monitoring: The alemtuzumab in multiple sclerosis safety systems (AMS3) study.

Reddel SW, Barnett MH, Riminton S, Dugal T, Buzzard K, Wang CT, Fitzgerald F, Beadnall HN, Erickson D, Gahan D, Wang D, Ackland T, Thompson R.

Mult Scler. 2018 Jun 1:1352458518783673. doi: 10.1177/1352458518783673. [Epub ahead of print]

PMID:
29911471
2.

Diffusivity in the core of chronic multiple sclerosis lesions.

Klistorner A, Wang C, Yiannikas C, Parratt J, Barton J, You Y, Graham SL, Barnett MH.

PLoS One. 2018 Apr 25;13(4):e0194142. doi: 10.1371/journal.pone.0194142. eCollection 2018.

3.

We should focus more on finding therapeutic targets for the non-inflammatory damage in MS - Yes.

Garber JY, Barnett MH.

Mult Scler. 2018 Sep;24(10):1272-1274. doi: 10.1177/1352458518770970. Epub 2018 Apr 16. No abstract available.

PMID:
29656673
4.

The evolution of "No Evidence of Disease Activity" in multiple sclerosis.

Lu G, Beadnall HN, Barton J, Hardy TA, Wang C, Barnett MH.

Mult Scler Relat Disord. 2018 Feb;20:231-238. doi: 10.1016/j.msard.2017.12.016. Epub 2017 Dec 25. Review.

PMID:
29579629
5.

Evidence of progressive tissue loss in the core of chronic MS lesions: A longitudinal DTI study.

Klistorner A, Wang C, Yiannikas C, Parratt J, Dwyer M, Barton J, Graham SL, You Y, Liu S, Barnett MH.

Neuroimage Clin. 2017 Dec 8;17:1028-1035. doi: 10.1016/j.nicl.2017.12.010. eCollection 2018.

6.

White matter tract-specific quantitative analysis in multiple sclerosis: Comparison of optic radiation reconstruction techniques.

Wang C, Klistorner A, Ly L, Barnett MH.

PLoS One. 2018 Jan 17;13(1):e0191131. doi: 10.1371/journal.pone.0191131. eCollection 2018.

7.

Progressive inner nuclear layer dysfunction in non-optic neuritis eyes in MS.

You Y, Graham EC, Shen T, Yiannikas C, Parratt J, Gupta V, Barton J, Dwyer M, Barnett MH, Fraser CL, Graham SL, Klistorner A.

Neurol Neuroimmunol Neuroinflamm. 2017 Dec 15;5(1):e427. doi: 10.1212/NXI.0000000000000427. eCollection 2018 Jan. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2018 Jan 31;5(2):e444.

8.

Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination.

Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VSC, White OB, Broadley S, Lechner-Scott J, Vucic S, Henderson APD, Barnett MH, Reddel SW, Brilot F, Dale RC; Australasian and New Zealand MOG Study Group.

J Neurol Neurosurg Psychiatry. 2018 Feb;89(2):127-137. doi: 10.1136/jnnp-2017-316880. Epub 2017 Nov 15.

9.

Exosomal microRNA signatures in multiple sclerosis reflect disease status.

Ebrahimkhani S, Vafaee F, Young PE, Hur SSJ, Hawke S, Devenney E, Beadnall H, Barnett MH, Suter CM, Buckland ME.

Sci Rep. 2017 Oct 30;7(1):14293. doi: 10.1038/s41598-017-14301-3.

10.

Vestibulo-ocular reflex deficits with medial longitudinal fasciculus lesions.

Aw ST, Chen L, Todd MJ, Barnett MH, Halmagyi GM.

J Neurol. 2017 Oct;264(10):2119-2129. doi: 10.1007/s00415-017-8607-8. Epub 2017 Sep 6.

PMID:
28879396
11.

Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.

Lorscheider J, Jokubaitis VG, Spelman T, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Trojano M, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Pucci E, Boz C, Sola P, Ferraro D, Spitaleri D, Lechner-Scott J, Terzi M, Van Pesch V, Iuliano G, Bergamaschi R, Ramo-Tello C, Granella F, Oreja-Guevara C, Butzkueven H, Kalincik T; MSBase Study Group.

Neurology. 2017 Sep 5;89(10):1050-1059. doi: 10.1212/WNL.0000000000004330. Epub 2017 Aug 9.

12.

Autoantibody responses to nodal and paranodal antigens in chronic inflammatory neuropathies.

Mathey EK, Garg N, Park SB, Nguyen T, Baker S, Yuki N, Yiannikas C, Lin CS, Spies JM, Ghaoui R, Barnett MH, Vucic S, Pollard JD, Kiernan MC.

J Neuroimmunol. 2017 Aug 15;309:41-46. doi: 10.1016/j.jneuroim.2017.05.002. Epub 2017 May 13.

PMID:
28601286
13.

Maternal autoimmunity: risk of neurodevelopmental and neuropsychiatric outcomes.

Dale RC, Barnett MH, Kiernan MC.

J Neurol Neurosurg Psychiatry. 2017 Sep;88(9):713-714. doi: 10.1136/jnnp-2017-315724. Epub 2017 Jun 8. No abstract available.

PMID:
28596249
14.

Incidence and prevalence of NMOSD in Australia and New Zealand.

Bukhari W, Prain KM, Waters P, Woodhall M, O'Gorman CM, Clarke L, Silvestrini RA, Bundell CS, Abernethy D, Bhuta S, Blum S, Boggild M, Boundy K, Brew BJ, Brown M, Brownlee WJ, Butzkueven H, Carroll WM, Chen C, Coulthard A, Dale RC, Das C, Dear K, Fabis-Pedrini MJ, Fulcher D, Gillis D, Hawke S, Heard R, Henderson APD, Heshmat S, Hodgkinson S, Jimenez-Sanchez S, Killpatrick T, King J, Kneebone C, Kornberg AJ, Lechner-Scott J, Lin MW, Lynch C, Macdonell R, Mason DF, McCombe PA, Pender MP, Pereira JA, Pollard JD, Reddel SW, Shaw C, Spies J, Stankovich J, Sutton I, Vucic S, Walsh M, Wong RC, Yiu EM, Barnett MH, Kermode AG, Marriott MP, Parratt JDE, Slee M, Taylor BV, Willoughby E, Wilson RJ, Vincent A, Broadley SA.

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):632-638. doi: 10.1136/jnnp-2016-314839. Epub 2017 May 26.

PMID:
28550069
15.

Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis.

De Stefano N, Silva DG, Barnett MH.

CNS Drugs. 2017 Apr;31(4):289-305. doi: 10.1007/s40263-017-0415-2. Review.

16.

Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab.

Barton J, Hardy TA, Riminton S, Reddel SW, Barnett Y, Coles A, Barnett MH.

Neurology. 2017 Mar 7;88(10):1004-1006. doi: 10.1212/WNL.0000000000003694. Epub 2017 Feb 8. No abstract available.

PMID:
28179462
17.

Two Time Point MS Lesion Segmentation in Brain MRI: An Expectation-Maximization Framework.

Jain S, Ribbens A, Sima DM, Cambron M, De Keyser J, Wang C, Barnett MH, Van Huffel S, Maes F, Smeets D.

Front Neurosci. 2016 Dec 19;10:576. doi: 10.3389/fnins.2016.00576. eCollection 2016.

18.

Virus-related Merkel cell carcinoma complicating fingolimod treatment for multiple sclerosis.

Beadnall HN, Gill AJ, Riminton S, Barnett MH.

Neurology. 2016 Dec 13;87(24):2595-2597. Epub 2016 Nov 16. No abstract available.

PMID:
27856777
19.

Neurological deficit following stereotactic radiosurgery for trigeminal neuralgia.

Kemp S, Allan RS, Patanjali N, Barnett MH, Jonker BP.

J Clin Neurosci. 2016 Dec;34:229-231. doi: 10.1016/j.jocn.2016.09.029. Epub 2016 Oct 17.

PMID:
27760694
20.

Diffusivity in multiple sclerosis lesions: At the cutting edge?

Klistorner A, Wang C, Fofanova V, Barnett MH, Yiannikas C, Parratt J, You Y, Graham SL.

Neuroimage Clin. 2016 Jul 5;12:219-26. doi: 10.1016/j.nicl.2016.07.003. eCollection 2016.

21.

Atypical inflammatory demyelinating syndromes of the CNS.

Hardy TA, Reddel SW, Barnett MH, Palace J, Lucchinetti CF, Weinshenker BG.

Lancet Neurol. 2016 Aug;15(9):967-981. doi: 10.1016/S1474-4422(16)30043-6. Review.

PMID:
27478954
22.

Wallerian Degeneration in the Corticospinal Tract Following Tumefactive Demyelination: Conventional and Advanced Magnetic Resonance Imaging.

Hardy TA, Wang C, Beadnall HN, Lagopoulos J, Barnett Y, Klistorner A, Barnett MH.

Can J Neurol Sci. 2016 Sep;43(5):726-7. doi: 10.1017/cjn.2016.253. Epub 2016 Jul 15. No abstract available.

PMID:
27417915
23.

Defining secondary progressive multiple sclerosis.

Lorscheider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, Girard M, Duquette P, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Hupperts R, Alroughani R, Sola P, Boz C, Pucci E, Lechner-Scott J, Bergamaschi R, Oreja-Guevara C, Iuliano G, Van Pesch V, Granella F, Ramo-Tello C, Spitaleri D, Petersen T, Slee M, Verheul F, Ampapa R, Amato MP, McCombe P, Vucic S, Sánchez Menoyo JL, Cristiano E, Barnett MH, Hodgkinson S, Olascoaga J, Saladino ML, Gray O, Shaw C, Moore F, Butzkueven H, Kalincik T; MSBase Study Group.

Brain. 2016 Sep;139(Pt 9):2395-405. doi: 10.1093/brain/aww173. Epub 2016 Jul 7.

PMID:
27401521
24.

Progressive Loss of Retinal Ganglion Cells and Axons in Nonoptic Neuritis Eyes in Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study.

Graham EC, You Y, Yiannikas C, Garrick R, Parratt J, Barnett MH, Klistorner A.

Invest Ophthalmol Vis Sci. 2016 Apr 1;57(4):2311-7. doi: 10.1167/iovs.15-19047.

PMID:
27127930
25.

Automated brain volumetrics in multiple sclerosis: a step closer to clinical application.

Wang C, Beadnall HN, Hatton SN, Bader G, Tomic D, Silva DG, Barnett MH.

J Neurol Neurosurg Psychiatry. 2016 Jul;87(7):754-7. doi: 10.1136/jnnp-2015-312304. Epub 2016 Apr 12.

26.

Axonal damage in central and peripheral nervous system inflammatory demyelinating diseases: common and divergent pathways of tissue damage.

Barnett MH, Mathey E, Kiernan MC, Pollard JD.

Curr Opin Neurol. 2016 Jun;29(3):213-21. doi: 10.1097/WCO.0000000000000334. Review.

PMID:
27058223
27.

Plasma levels of endothelial and B-cell-derived microparticles are restored by fingolimod treatment in multiple sclerosis patients.

Zinger A, Latham SL, Combes V, Byrne S, Barnett MH, Hawke S, Grau GE.

Mult Scler. 2016 Dec;22(14):1883-1887. Epub 2016 Mar 1.

PMID:
26931477
28.

Migration and multiple sclerosis in immigrants from United Kingdom and Ireland to Australia: a reassessment. III: risk of multiple sclerosis in UKI immigrants and Australian-born in Hobart, Tasmania.

Barnett MH, McLeod JG, Hammond SR, Kurtzke JF.

J Neurol. 2016 Apr;263(4):792-8. doi: 10.1007/s00415-016-8059-6. Epub 2016 Feb 25.

PMID:
26914927
29.

Progressive Injury in Chronic Multiple Sclerosis Lesions Is Gender-Specific: A DTI Study.

Klistorner A, Wang C, Yiannikas C, Graham SL, Parratt J, Barnett MH.

PLoS One. 2016 Feb 22;11(2):e0149245. doi: 10.1371/journal.pone.0149245. eCollection 2016.

30.

Acute bulbar, neck and limb weakness with monospecific anti-GT1a antibody: A rare localized subtype of Guillain-Barré syndrome.

Garg N, Yuki N, Park SB, Barnett MH, Kiernan MC.

Muscle Nerve. 2016 Jan;53(1):143-6. doi: 10.1002/mus.24935. Epub 2015 Nov 23.

PMID:
26452439
31.

A new era in the treatment of multiple sclerosis.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies JM, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E.

Med J Aust. 2015 Aug 3;203(3):139-41, 141e.1. Review.

PMID:
26224184
32.

A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis.

Gu BJ, Field J, Dutertre S, Ou A, Kilpatrick TJ, Lechner-Scott J, Scott R, Lea R, Taylor BV, Stankovich J, Butzkueven H, Gresle M, Laws SM, Petrou S, Hoffjan S, Akkad DA, Graham CA, Hawkins S, Glaser A, Bedri SK, Hillert J, Matute C, Antiguedad A; ANZgene Consortium, Wiley JS.

Hum Mol Genet. 2015 Oct 1;24(19):5644-54. doi: 10.1093/hmg/ddv278. Epub 2015 Jul 17.

PMID:
26188005
33.

Tablet-based screening improves continence management in multiple sclerosis.

Beadnall HN, Kuppanda KE, O'Connell A, Hardy TA, Reddel SW, Barnett MH.

Ann Clin Transl Neurol. 2015 Jun;2(6):679-87. doi: 10.1002/acn3.205. Epub 2015 May 1.

34.

The corpus callosum in the diagnosis of multiple sclerosis and other CNS demyelinating and inflammatory diseases.

Garg N, Reddel SW, Miller DH, Chataway J, Riminton DS, Barnett Y, Masters L, Barnett MH, Hardy TA.

J Neurol Neurosurg Psychiatry. 2015 Dec;86(12):1374-82. doi: 10.1136/jnnp-2014-309649. Epub 2015 Apr 9. Review.

PMID:
25857658
35.

Decoding diffusivity in multiple sclerosis: analysis of optic radiation lesional and non-lesional white matter.

Klistorner A, Vootakuru N, Wang C, Yiannikas C, Graham SL, Parratt J, Garrick R, Levin N, Masters L, Lagopoulos J, Barnett MH.

PLoS One. 2015 Mar 25;10(3):e0122114. doi: 10.1371/journal.pone.0122114. eCollection 2015.

36.

Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype.

Mathey EK, Park SB, Hughes RA, Pollard JD, Armati PJ, Barnett MH, Taylor BV, Dyck PJ, Kiernan MC, Lin CS.

J Neurol Neurosurg Psychiatry. 2015 Sep;86(9):973-85. doi: 10.1136/jnnp-2014-309697. Epub 2015 Feb 12. Review.

37.

Distinguishing Susac's syndrome from multiple sclerosis.

Buzzard KA, Reddel SW, Yiannikas C, Sean Riminton D, Barnett MH, Hardy TA.

J Neurol. 2015 Jul;262(7):1613-21. doi: 10.1007/s00415-014-7628-9. Epub 2014 Dec 30. Review.

PMID:
25547511
38.

Baló's concentric sclerosis and tumefactive demyelination: a shared immunopathogenesis?

Hardy TA, Beadnall HN, Sutton IJ, Mohamed A, Jonker BP, Buckland ME, Barnett MH.

J Neurol Sci. 2015 Jan 15;348(1-2):279-81. doi: 10.1016/j.jns.2014.11.024. Epub 2014 Nov 25.

PMID:
25475150
39.

Axonal conduction in multiple sclerosis: A combined magnetic resonance imaging and electrophysiological study of the medial longitudinal fasciculus.

Wang C, Paling D, Chen L, Hatton SN, Lagopoulos J, Aw ST, Kiernan MC, Barnett MH.

Mult Scler. 2015 Jun;21(7):905-15. doi: 10.1177/1352458514556301. Epub 2014 Nov 12.

PMID:
25392333
40.

Brain histopathology in three cases of Susac's syndrome: implications for lesion pathogenesis and treatment.

Hardy TA, O'Brien B, Gerbis N, Barnett MH, Reddel SW, Brewer J, Herkes GK, Silberstein P, Garsia RJ, Watson JD, Gupta R, Parratt JD, Buckland ME.

J Neurol Neurosurg Psychiatry. 2015 May;86(5):582-4. doi: 10.1136/jnnp-2014-308240. Epub 2014 Aug 28. No abstract available.

PMID:
25168394
41.

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of Neurologists.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E; MS Neurology Group of the Australian and New Zealand Association of Neurologists.

J Clin Neurosci. 2014 Nov;21(11):1857-65. doi: 10.1016/j.jocn.2014.01.017. Epub 2014 Jun 30. Review.

PMID:
24993136
42.

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of Neurologists.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E; MS Neurology Group of the Australian and New Zealand Association of Neurologists.

J Clin Neurosci. 2014 Nov;21(11):1835-46. doi: 10.1016/j.jocn.2014.01.016. Epub 2014 Jun 30. Review.

PMID:
24993135
43.

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neurologists.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E; MS Neurology Group of the Australian and New Zealand Association of Neurologists.

J Clin Neurosci. 2014 Nov;21(11):1847-56. doi: 10.1016/j.jocn.2014.01.018. Epub 2014 Jun 28. Review.

PMID:
24986155
44.

Axonal loss of retinal neurons in multiple sclerosis associated with optic radiation lesions.

Klistorner A, Sriram P, Vootakuru N, Wang C, Barnett MH, Garrick R, Parratt J, Levin N, Raz N, Van der Walt A, Masters L, Graham SL, Yiannikas C.

Neurology. 2014 Jun 17;82(24):2165-72. doi: 10.1212/WNL.0000000000000522. Epub 2014 May 16.

45.

Latency of multifocal visual evoked potentials in nonoptic neuritis eyes of multiple sclerosis patients associated with optic radiation lesions.

Alshowaeir D, Yiannikas C, Garrick R, Parratt J, Barnett MH, Graham SL, Klistorner A.

Invest Ophthalmol Vis Sci. 2014 May 15;55(6):3758-64. doi: 10.1167/iovs.14-14571.

PMID:
24833744
46.

Progressive neuropsychiatric symptoms and motor impairment.

Ghadiri M, Buckland ME, Sutton IJ, Al Jahdhami S, Flanagan S, Heard R, Barnett Y, Brennan J, Barnett MH.

JAMA Neurol. 2014 Jun;71(6):794-8. doi: 10.1001/jamaneurol.2013.6308.

PMID:
24711011
47.

Inner nuclear layer thickening is inversley proportional to retinal ganglion cell loss in optic neuritis.

Kaushik M, Wang CY, Barnett MH, Garrick R, Parratt J, Graham SL, Sriram P, Yiannikas C, Klistorner A.

PLoS One. 2013 Oct 3;8(10):e78341. doi: 10.1371/journal.pone.0078341. eCollection 2013.

48.

Conventional and advanced imaging in neuromyelitis optica.

Barnett Y, Sutton IJ, Ghadiri M, Masters L, Zivadinov R, Barnett MH.

AJNR Am J Neuroradiol. 2014 Aug;35(8):1458-66. doi: 10.3174/ajnr.A3592. Epub 2013 Jun 13. Review.

49.

The thalamus and multiple sclerosis: modern views on pathologic, imaging, and clinical aspects.

Minagar A, Barnett MH, Benedict RH, Pelletier D, Pirko I, Sahraian MA, Frohman E, Zivadinov R.

Neurology. 2013 Jan 8;80(2):210-9. doi: 10.1212/WNL.0b013e31827b910b. Review.

50.

Axonal loss in non-optic neuritis eyes of patients with multiple sclerosis linked to delayed visual evoked potential.

Klistorner A, Garrick R, Barnett MH, Graham SL, Arvind H, Sriram P, Yiannikas C.

Neurology. 2013 Jan 15;80(3):242-5. doi: 10.1212/WNL.0b013e31827deb39. Epub 2012 Dec 26.

PMID:
23269599

Supplemental Content

Loading ...
Support Center